This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
keyboard_arrow_right

MAIN CONFERENCE DAY FOUR

keyboard_arrow_leftSearch & Filter
search

MAIN CONFERENCE DAY FOUR

search
7:45am - 8:15am30 mins
Breakfast Presentation: Empowering Therapeutic Development with Customized N-Glycosylation Solutions
  • Sylvain Marcel - Vice President – Protein Expression Sciences, iBio CDMO
8:25am - 8:30am5 mins
Track 1: Targeting Subcellular Trafficking Pathways to Generate Antibody Therapeutics
Chairwoman’s Remarks
  • Sally Ward, PhD - Professor, University of Southampton and Texas A&M University Health Science Center
8:25am - 8:30am5 mins
Track 2: Tumor-conditional Immunotherapy
Chairman’s Remarks
  • Karl Dane Wittrup, Ph.D. - C.P. Dubbs Professor, Massachusetts Institute of Technology
8:30am - 9:00am30 mins
Track 2: Tumor-conditional Immunotherapy
Hot is Not Enough. Using In Situ Vaccine to Make Cold Tumors Hot and Cross-Priming
  • Joshua Brody, M.D. - Director, Lymphoma Immunotherapy Program, Icahn School of Medicine at Mount Sinai
8:30am - 9:00am30 mins
Track 1: Targeting Subcellular Trafficking Pathways to Generate Antibody Therapeutics
Isoelectric Point Engineering to Enhance the Potency of Therapeutic Antibody
  • Taichi Kuramochi - Research Manager, Chugai Pharmabody Research Pte. Ltd.
9:00am - 9:30am30 mins
Track 2: Tumor-conditional Immunotherapy
Intratumoral Collagen-retained Immunotherapy
  • Noor Momin - Biological Engineering Doctoral Candidate, Massachusetts Institute of Technology
9:00am - 9:30am30 mins
Track 1: Targeting Subcellular Trafficking Pathways to Generate Antibody Therapeutics
Design and Preclinical Characterization of ULTOMIRIS
  • Douglas Sheridan - Global Program Leader, RallyBio
9:30am - 10:00am30 mins
Track 1: Targeting Subcellular Trafficking Pathways to Generate Antibody Therapeutics
Rozanolixizumab, A Subcutaneously Delivered IgG4 mAb Targeting FcRn for the Treatment of IgG Autoantibody-driven disorders
  • Anthony Shock - Director, UCB Pharma
9:30am - 10:00am30 mins
Track 2: Tumor-conditional Immunotherapy
Localized Delivery of a CD47 Blocking Nanobody Enhances Immunotherapy Responses
  • Michael Dougan - Assistant Professor of Medicine, Massachusetts General Hospital
10:00am - 10:30am30 mins
Networking Refreshment Break
    10:30am - 11:00am30 mins
    Track 2: Tumor-conditional Immunotherapy
    Drugging the Tumor Immune Microenvironment: Disease Effects on Antibody Availability and Activity within Tumors and Lymphoid Tissues
    • Susan Thomas - Associate Professor, Georgia Institute of Technology
    10:30am - 11:00am30 mins
    Track 1: Targeting Subcellular Trafficking Pathways to Generate Antibody Therapeutics
    Efgartigimod, A Novel FcRn Antagonist, For the Treatment of Patients with Severe Autoimmune Diseases
    • Hans de Haard, PhD - Chief Scientific Officer, Argenx
    11:00am - 11:30am30 mins
    Track 1: Targeting Subcellular Trafficking Pathways to Generate Antibody Therapeutics
    Cytokine-mediated Enhancement of FcγRI Clustering and Signaling
    • Jeanette Leusen, PhD - Associate Professor, Head Immunotherapy Group, University Medical Center Utrecht
    11:00am - 11:30am30 mins
    Track 2: Tumor-conditional Immunotherapy
    COBRA – A Novel Class of Conditionally Active, T-cell Engaging Bispecifics for the Treatment of Solid Tumors
    • Bob Dubridge - EVP of Research, Maverick Therapeutics
    11:30am - 12:00pm30 mins
    Track 1: Targeting Subcellular Trafficking Pathways to Generate Antibody Therapeutics
    Roles of FcγRIIB in Regulating Antibody Therapy
    • Mark Cragg, PhD - Chair in Experimental Cancer Biology, University of Southampton
    11:30am - 12:00pm30 mins
    Track 2: Tumor-conditional Immunotherapy
    Redirection of Immunity Against Cancer using Antibody Circuits
    • Mark Cobbold, M.D., Ph.D. - Vice President, Discovery Oncology, AstraZeneca
    12:00pm - 1:25pm85 mins
    Networking Luncheon
      1:25pm - 1:30pm5 mins
      Track 1: Special Joint Session with the Chinese Antibody Society
      Co-Chairs’ Remarks
      • Kerry Chester, PhD - Professor of Molecular Medicine, UCL Cancer Institute
      • Mitchell Ho, PhD - Senior Investigator, Laboratory of Molecular Biology, NIH NCI
      1:25pm - 1:30pm5 mins
      Track 2: Looking at Targets Differently
      Co-Chairs Remarks
      • Janine Schuurman, Ph.D. - Corporate Vice President Research & Innovation, Genmab
      • James Ernst, Ph.D. - Senior Director, Head of Development Sciences, Xencor
      1:30pm - 2:00pm30 mins
      Track 2: Looking at Targets Differently
      Antibody-mediated Inhibition of MICA/B Shedding by Tumor Cells Promotes NK Cell Recognition
      • Lucas Ferrari de Andrade - Assistant Professor, Department of Oncologic, Icahn School of Medicine at Mount Sinai
      1:30pm - 2:00pm30 mins
      Track 1: Special Joint Session with the Chinese Antibody Society
      China/UK Development of a FDC Tailored for Difficult to Treat Solid Tumors
      • Mahendra Deonarain, PhD - Chief Executive and Science Officer, Antikor Biopharma Ltd
      2:00pm - 2:30pm30 mins
      Track 1: Special Joint Session with the Chinese Antibody Society
      WuXiBodyTM, An Innovative and Versatile Bispecific Antibody Format Opens a New Era for Therapeutic Antibody Development
      • Jing Li, MD, PhD, MBA - Senior Vice President, Biologics Discovery, WuXi Biologics
      2:00pm - 2:30pm30 mins
      Track 2: Looking at Targets Differently
      Therapeutic IgG Antibody Combinations Acting as Bio-Logic AND Gates
      • Robert de Jong - Associate Director Antibody Research & Technology, Genmab
      2:30pm - 3:00pm30 mins
      Track 1: Special Joint Session with the Chinese Antibody Society
      TCR-mimic Antibodies against Intracellular Target for Cancer Immunotherapy: Targeting Alpha-fetoprotein (AFP) in Advanced Hepatocellular Carcinoma
      • Cheng Liu - Founder & CEO, Eureka Therapeutics, Inc.
      2:30pm - 3:00pm30 mins
      Track 2: Looking at Targets Differently
      Redirected Optimized Cell Killing (ROCK®): A Multispecific Antibody Platform For Innate Immune Cell Engagement
      • Michael Tesar, Ph.D. - Research Program Head, Affimed
      3:00pm - 3:30pm30 mins
      Networking Refreshment Break
        3:30pm - 4:00pm30 mins
        Track 1: Special Joint Session with the Chinese Antibody Society
        Durable Blockade of PD-1 Signaling Links Preclinical Efficacy of Sintilimab to its Clinical Benefit
        • Junjian Liu, PhD - Vice President, Head of Drug Discovery, Innovent Biologics, Inc.
        3:30pm - 4:00pm30 mins
        Track 2: Looking at Targets Differently
        De Novo Design of Potent and Selective Protein Cytokine Mimics
        • Daniel-Adriano Silva, PhD - VP, Head of Research, Neoleukin Therapeutics
        4:00pm - 4:30pm30 mins
        Track 1: Special Joint Session with the Chinese Antibody Society
        Development of Cancer-reactive Antibodies Focused to the 287-302 Amino Acid Loop of the Human Epidermal Growth Factor Receptor
        • Eric Chun Hei Ho, PhD - Post-Doctoral Fellow, NIH, NCI
        4:00pm - 4:30pm30 mins
        Track 2: Looking at Targets Differently
        Harnessing Neoantigens for Cancer Immunotherapy
        • Lélia Delamarre - Senior Scientist, Cancer Immunology Discovery, Genentech
        4:30pm - 5:00pm30 mins
        Track 1: Special Joint Session with the Chinese Antibody Society
        Engineered Antibody Domains for Therapy of Cancer and AIDS
        • Dimiter Dimitrov, PhD - Professor and Director, Center for Antibody Therapeutics, University of Pittsburgh Medical School
        4:30pm - 5:00pm30 mins
        Track 2: Looking at Targets Differently
        T-cell Targets – Identification and Clinical Use
        • Toni Weinschenk - Chief Technology Officer, Immatics Biotechnologies
        5:00pm - 5:05pm5 mins
        Close of Conference
          MAIN CONFERENCE DAY THREE

          Get the latest news.
          As it happens

          Sign up to get the latest on the agenda and speakers.
          Filter
          Streams
          Formats
          Choose Day